GSK: promising results in relapsed myeloma

(CercleFinance.com) - GSK announces that an interim analysis of a Phase III trial has met its primary secondary endpoint of overall survival in relapsed or refractory multiple myeloma with Blenrep (belantamab mafodotin) in combination with bortezomib and dexamethasone (BorDex).


The results showed a significant reduction in the risk of death compared with standard treatment (daratumumab + BorDex)

This is a statistically significant and clinically important advance for patients, potentially transformative for treatment. We look forward to sharing these data with healthcare authorities and presenting the full results at the upcoming American Society of Hematology annual meeting, said Hesham Abdullah, Senior Vice President, Global Head Oncology, R&D at GSK.

Results will be presented at the 66th ASH Congress on 9 December 2024.


Copyright (c) 2024 CercleFinance.com. All rights reserved.